ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2025
Chlamydia muridarum Infection Impacts Murine Models of Intestinal Inflammation and Cancer.
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
Chlamydia muridarum has reemerged as a prevalent infectious agent in research mouse colonies. Despite its prevalence and ability to persistently colonize the murine gastrointestinal tract, few studies have evaluated the potential impact of C. muridarum on experimental models of gastrointestinal disease. Studies were conducted to evaluate the impact of C. muridarum on the Citrobacter rodentium, Trichuris muris, and Il10-/- mouse models of intestinal inflammation, as well as on tumorigenesis in the ApcMin/+ mouse following administration of dextran sodium sulfate (DSS). Naïve C57BL/6J (B6), B6.129P2-Il10tm1Cgn/J (Il10-/-), and C57BL/6J-ApcMin/J (ApcMin/+) mice were infected with C. muridarum by cohousing with chronic C. muridarum-shedding BALB/cJ mice for 2 weeks; controls were cohoused with C. muridarum-free mice. After cohousing, B6 mice (n = 8 C. muridarum infected and free) were infected with C. rodentium (109 CFU orally) or T. muris (200 ova orally). Il10-/- mice (n = 8/group with and without Helicobacter hepaticus [108 CFU/mouse] and with and without C. muridarum) and ApcMin/+ mice (n = 8/group) that received 2% DSS for 7 days in drinking water after cohousing. Mice were euthanized 14 days post-C. rodentium infection, 18 days post-T. muris infection, 60 days post-H. hepaticus infection, or control with Il10-/- mice, and 28 days post-DSS administration to ApcMin/+ mice. The severity of the cecal and colonic lesions was evaluated and graded using a tiered, semiquantitative scoring system. C. muridarum infection attenuated colitis associated with C. rodentium (P = 0.03), had no effect on T. muris-associated pathology (P = 0.22), worsened colitis in Il10-/- mice in the absence of H. hepaticus (P = 0.007), and reduced chemically induced colonic tumorigenesis in ApcMin/+ mice (P = 0.004). Thus, C. muridarum colonization differentially impacts several models of intestinal inflammation and tumorigenesis, and the presence of this bacterium in mouse colonies should be considered as a variable in these experimental readouts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.